Involvement of cannabinoid receptors in gut motility and visceral perception

British Journal of Pharmacology

Volumn 141, Issue 8, 2004, Pages 1335-1345

  Hornby, Pamela J ^a   Prouty, Stephen M ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Anandamide; Delta 9 tetrahydrocannabinol; Emesis; Endocannabinoid; Gastroesophageal reflux disease; Ileitis; Intestine; Lower oesophageal sphincter; Stomach

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; ANTACID AGENT; ANTIEMETIC AGENT; APPETITE STIMULANT; ARACHIDONIC ACID; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CAPSAICIN; DEXANABINOL; DRONABINOL; FATTY ACID AMIDASE; HEXAMETHONIUM; HISTAMINE H2 RECEPTOR ANTAGONIST; METHANANDAMIDE; NALOXONE; PROTON PUMP INHIBITOR; RIMONABANT; UNCLASSIFIED DRUG; VIRODHAMINE;

BRAIN; DRUG SYNTHESIS; ENTEROPATHY; GASTROINTESTINAL TRACT; HUMAN; IMMUNOCOMPETENT CELL; INTESTINE FUNCTION DISORDER; INTESTINE INNERVATION; INTESTINE MOTILITY; IRRITABLE COLON; PAIN; PRIORITY JOURNAL; REVIEW; STOMACH DISTENSION;

ANIMALS; ENDOCANNABINOIDS; GASTROINTESTINAL MOTILITY; HUMANS; PAIN THRESHOLD; RECEPTORS, CANNABINOID; VISCERAL AFFERENTS;

EID: 2442535168     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705783     Document Type: Review

References (106)

1. ADAMI, M., CORUZZI, G., SOLDANI, G., TODOROV, S., ZAMFIROVA, R., STAVREV, E., BROWN, D.R. & KULKARNI-NARLA, A. (2001). Investigation of CB1R cannabinoid receptos mediating antisecretory effects in rat stomach. Br. J. Pharmacol., 133, 244P.
2. ADAMI, M., FRATI, P., BERTINI, S., KULKARNI-NARLA, A., BROWN, D.R., DE CARO, G., CORUZZI, G. & SOLDANI, G. (2002). Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br. J. Pharmacol., 135, 1598-1606.
3. BALL, A.J., MOERSCHBAECHER, J.M. & HORNBY, P.J. (2001). Delta 9-tetrahydrocannabinol effects on gastric motility are mediated by a capsacin-sensitive vagal pathway. Digestion, 63, 269.
4. BARTHO, L., BENKO, R., LAZAR, Z., ILLENYI, L. & HORVATH, O.P. (2002). Nitric oxide is involved in the relaxant effect of capsaicin in the human sigmoid colon circular muscle. Naunyn Schmiedebergs Arch. Pharmacol., 366, 496-500.
5. BELTRAMO, M. & PIOMELLI, D. (2000). Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport, 11, 1231-1235.
6. BISOGNO, T., DE PETROCELLIS, L. & DI MARZO, V. (2002). Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr. Pharm. Des., 8, 533-547.
7. BISOGNO, T., SEPE, N., MELCK, D., MAURELLI, S., DE PETROCELLIS, L. & DI MARZO, V. (1997). Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J., 322 (Part 2), 671-677.
8. BROWN, S.P., BRENOWITZ, S.D. & REGEHR, W.G. (2003). Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids. Nat. Neurosci., 6, 1048-1057.
9. BURDYGA, G., LAL, S., VARRO, A., DIMALINE, R., THOMPSON, D.G. & DOCKRAY, G.J. (2004). Expression of cannbinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J. Neurosci., 24, 2708-2715.
10. CADAS, H., DI TOMASO, E. & PIOMELLI, D. (1997). Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci., 17, 1226-1242.
11. CAPASSO, R., IZZO, A.A., FEZZA, F., PINTO, A., CAPASSO, F., MASCOLO, N. & DI MARZO, V. (2001). Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br. J. Pharmacol., 134, 945-950.
12. CASU, M.A., PORCELLA, A., RUIU, S., SABA, P., MARCHESE, G., CARAI, M.A., REALI, R., GESSA, G.L. & PANI, L. (2003). Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. Eur. J. Pharmacol., 459, 97-105.
13. CICHEWICZ, D.L. & WELCH, S.P. (2003). Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther., 305, 812-817.
14. CORUZZI, G., ADAMI, M., COPPELLI, G., FRATI, P. & SOLDANI, G. (1999). Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedebergs Arch. Pharmacol., 360, 715-718.
15. COSTA, B., COLLEONI, M., CONTI, S., TROVATO, A.E., BIANCHI, M., SOTGIU, M.L. & GIAGNONI, G. (2004). Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br. J. Pharmacol., 141, 4-8.
16. COUTTS, A.A., IRVING, A.J., MACKIE, K., PERTWEE, R.G. & ANAVI-GOFFER, S. (2002). Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J. Comp. Neurol., 448, 410-422.
17. COUTTS, A.A. & PERTWEE, R.G. (1997). Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br. J. Pharmacol., 121, 1557-1566.
18. DARMANI, N.A. (2001). The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur. J. Pharmacol., 430, 49-58.
19. DARMANI, N.A., JANOYAN, J.J., KUMAR, N. & CRIM, J.L. (2003a). Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol. Biochem. Behav., 75, 777-787.
20. DARMANI, N.A., SIM-SELLEY, L.J., MARTIN, B.R., JANOYAN, J.J., CRIM, J.L., PAREKH, B. & BREIVOGEL, C.S. (2003b). Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation. Eur. J. Pharmacol., 459, 83-95.
21. DAY, T.A., RAKHSHAN, F., DEUTSCH, D.G. & BARKER, E.L. (2001). Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol., 59, 1369-1375.
22. DERBENEV, A.V. & SMITH, B.N. (2003). Endocannabinoids interact with CB1 and VR1 receptors on GABAergic synaptic terminals contacting rat vagal motor neurons. Soc. Neurosci. Abstr., 33.
23. DERBENEV, A.V., STUART, T.C. & SMITH, B.N. (2002). Alteration of synpatic transmission by cannabinoids in rat brainstem vagal complex. Soc. Neurosci. Abstr., 32, 830.
24. DEUTSCH, D.G., UEDA, N. & YAMAMOTO, S. (2002). The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot. Essent. Fatty Acids, 66, 201-210.
25. DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
26. DI CARLO, G. & IZZO, A.A. (2003). Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin. Investig. Drugs, 12, 39-49.
27. DI MARZO, V., BISOGNO, T., DE PETROCELLIS, L., MELCK, D., ORLANDO, P., WAGNER, J.A. & KUNOS, G. (1999). Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem., 264, 258-267.
28. DINH, T.P., CARPENTER, D., LESLIE, F.M., FREUND, T.F., KATONA, I., SENSI, S.L., KATHURIA, S. & PIOMELLI, D. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A., 99, 10819-10824.
29. EARLEYWINE, M. (2002). Understanding Marijuana. Oxford: Oxford University Press.
30. FOWLER, C.J. & JACOBSSON, S.O. (2002). Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide - targets for drug development? Prostaglandins Leukot. Essent. Fatty Acids, 66, 193-200.
31. FREUND, T.F., KATONA, I. & PIOMELLI, D. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev., 83, 1017-1066.
32. FRIDE, E. (2002). Endocannabinoids in the central nervous system-an overview. Prostaglandins Leukot. Essent. Fatty Acids, 66, 221-233.
33. GERARD, C.M., MOLLEREAU, C., VASSART, G. & PARMENTIER, M. (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J., 279 (Part 1), 129-134.
34. GERMANO, M.P., D'ANGELO, V., MONDELLO, M.R., PERGOLIZZI, S., CAPASSO, F., CAPASSO, R., IZZO, A.A., MASCOLO, N. & DE PASQUALE, R. (2001). Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats. Naunyn Schmiedebergs Arch. Pharmacol., 363, 241-244.
35. GOPARAJU, S.K., UEDA, N., TANIGUCHI, K. & YAMAMOTO, S. (1999). Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem. Pharmacol., 57, 417-423.
36. HANSEN, H.H., IKONOMIDOU, C., BITTIGAU, P., HANSEN, S.H. & HANSEN, H.S. (2001). Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J. Neurochem., 76, 39-46.
37. HANUS, L., ABU-LAFI, S., FRIDE, E., BREUER, A., VOGEL, Z., SHALEV, D.E., KUSTANOVICH, I. & MECHOULAM, R. (2001). 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U.S.A., 98, 3662-3665.
38. HEINEMANN, A., Shahbazian, A. & HOLZER, P. (1999). Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology, 38, 1289-1297.
39. HILLARD, C.J., EDGEMOND, W.S., JARRAHIAN, A. & CAMPBELL, W.B. (1997). Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem., 69, 631-638.
40. HILLARD, C.J. & JARRAHIAN, A. (2003). Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol., 140, 802-808.
41. HILLARD, C.J. & JARRAHIAN, A. (2000). The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids, 108, 123-134.
42. HINE, B., FRIEDMAN, E., TORRELIO, M. & GERSHON, S. (1975). Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science, 187, 443-445.
43. HOHMANN, A.G. & HERKENHAM, M. (1999). Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience, 90, 923-931.
44. HOLLOWAY, R.H. & DENT, J. (1990). Pathophysiology of gastroesophageal reflux. Lower esophageal sphincter dysfunction in gastroesophageal reflux disease. Gastroenterol. Clin. N. Am., 19, 517-535.
45. HORNBY, P.J. (2001). Central neurocircuitry associated with emesis. Am. J. Med., 111, 106S-112S.
46. HORNBY, P.J., ABRAHAMS, T.P. & PARTOSOEDARSO, E.R. (2002). Central mechanisms of lower esophageal sphincter control. Gastroenterol. Clin. N. Am., 31, S11-S20 v-vi.
47. IZZO, A.A., CAPASSO, F., COSTAGLIOLA, A., BISOGNO, T., MARSICANO, G., LIGRESTI, A., MATIAS, I., CAPASSO, R., PINTO, L., BORRELLI, F., CECIO, A., LUTZ, B., MASCOLO, N. & DIMARZO, V. (2003). An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology, 125, 765-774.
48. IZZO, A.A., FEZZA, F., CAPASSO, R., BISOGNO, T., PINTO, L., IUVONE, T., ESPOSITO, G., MASCOLO, N., DI MARZO, V. & CAPASSO, F. (2001). Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol., 134, 563-570.
49. IZZO, A.A., MASCOLO, N., CAPASSO, R., GERMANO, M.P., DE PASQUALE, R. & CAPASSO, F. (1999a). Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedebergs Arch. Pharmacol., 360, 221-223.
50. IZZO, A.A., MASCOLO, N., PINTO, L., CAPASSO, R. & CAPASSO, F. (1999b). The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur. J. Pharmacol., 384, 37-42.
51. IZZO, A.A., PINTO, L., BORRELLI, F., CAPASSO, R., MASCOLO, N. & CAPASSO, F. (2000). Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br. J. Pharmacol., 129, 1627-1632.
52. JARBE, T.U., SHEPPARD, R., LAMB, R.J., MAKRIYANNIS, A., LIN, S. & GOUTOPOULOS, A. (1998). Effects of delta-9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats. Behav. Pharmacol., 9, 169-174.
53. KATAYAMA, K., UEDA, N., KURAHASHI, Y., SUZUKI, H., YAMAMOTO, S. & KATO, I. (1997). Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim. Biophys. Acta., 1347, 212-218.
54. KOJIMA, S., SUGIURA, T., WAKU, K. & KAMIKAWA, Y. (2002). Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro. Eur. J. Pharmacol., 444, 203-207.
55. KOZAK, K.R. & MARNETT, L.J. (2002). Oxidative metabolism of endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids, 66, 211-220.
56. KROWICKI, Z.K., MOERSCHBAECHER, J.M., WINSAUER, P.J., DIGAVALLI, S.V. & HORNBY, P.J. (1999). Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur. J. Pharmacol., 371, 187-196.
57. KULKARNI-NARLA, A. & BROWN, D.R. (2000). Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res., 302, 73-80.
58. KURAHASHI, Y., UEDA, N., SUZUKI, H., SUZUKI, M. & YAMAMOTO, S. (1997). Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase. Biochem. Biophys. Res. Commun., 237, 512-515.
59. LEGGETT, J.D., ASPLEY, S., BECKETT, S.R., D'ANTONA, A.M. & KENDALL, D.A. (2004). Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br. J. Pharmacol., 141, 253-262.
60. LEHMANN, A., BLACKSHAW, L.A., BRANDEN, L., CARLSSON, A., JENSEN, J., NYGREN, E. & SMID, S.D. (2002). Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology, 123, 1129-1134.
61. LIDUMS, I., LEHMANN, A., CHECKLIN, H., DENT, J. & HOLLOWAY, R.H. (2000). Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology, 118, 7-13.
62. LOPEZ-RODRIGUEZ, M.L., VISO, A., ORTEGA-GUTIERREZ, S., FOWLER, C.J., TIGER, G., DE LAGO, E., FERNANDEZ-RUIZ, J. & RAMOS, J.A. (2003). Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J. Med. Chem., 46, 1512-1522.
63. MACNAUGHTON, W.K., VAN SICKLE, M.D., KEENAN, C.M., CUSHING, K., MACKIE, K. & SHARKEY, K.A. (2004). Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am. J. Physiol. Gastrointest Liver Physiol., (in press).
64. MANARA, L., CROCI, T., GUAGNINI, F., RINALDI-CARMONA, M., MAFFRAND, J.P., LE FUR, G., MUKENGE, S. & FERLA, G. (2002). Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig. Liver Dis., 34, 262-269.
65. MANCINELLI, R., FABRIZI, A., DEL MONACO, S., AZZENA, G.B., VARGIU, R., COLOMBO, G.C. & GESSA, G.L. (2001). Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. Life Sci., 69, 101-111.
66. MANG, C.F., ERBELDING, D. & KILBINGER, H. (2001). Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br. J. Pharmacol., 134, 161-167.
67. MASCOLO, N., IZZO, A.A., LIGRESTI, A., COSTAGLIOLA, A., PINTO, L., CASCIO, M.G., MAFFIA, P., CECIO, A., CAPASSO, F. & DI MARZO, V. (2002). The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J., 16, 1973-1975.
68. MATSUDA, L.A., LOLAIT, S.J., BROWNSTEIN, M.J., YOUNG, A.C. & BONNER, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564.
69. MCCALLUM, R.W., SOYKAN, I., SRIDHAR, K.R., RICCI, D.A., LANGE, R.C. & PLANKEY, M.W. (1999). Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment. Pharmacol. Ther., 13, 77-80.
70. MCVEY, D.C., SCHMID, P.C., SCHMID, H.H. & VIGNA, S.R. (2003). Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J. Pharmacol. Exp. Ther., 304, 713-722.
71. MECHOULAM, R., BEN-SHABAT, S., HANUS, L., LIGUMSKY, M., KAMINSKI, N.E., SCHATZ, A.R., GOPHER, A., ALMOG, S., MARTIN, B.R., COMPTON, D.R., PERTWEE, R.G., GRIFFIN, G., BAYEWITCH, M., BARG, J. & VOGEL, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50, 83-90.
72. MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65.
73. NALIN, D.R., LEVINE, M.M., RHEAD, J., BERGQUIST, E., RENNELS, M., HUGHES, T., O'DONNEL, S. & HORNICK, R.B. (1978). Cannabis, hypochlorhydria, and cholera. Lancet, 2, 859-862.
74. NAVARRO, M., CHOWEN, J., ROCIO, A.C.M., DEL ARCO, I., VILLANUA, M.A., MARTIN, Y., ROBERTS, A.J., KOOB, G.F. & DE FONSECA, F.R. (1998). CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. NeuroReport, 9, 3397-3402.
75. OKA, S., TSUCHIE, A., TOKUMURA, A., MURAMATSU, M., SUHARA, Y., TAKAYAMA, H., WAKU, K. & SUGIURA, T. (2003). Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem., 85, 1374-1381.
76. O'SHAUGHNESSY, W.B. (1842). On the preparation of Indian hemp or gunjah (Cannibis indica): the effects on the animal system in health, and their utility in the treatment of tetanus and other convulsant diseases. Trans. Med. Phys. Soc. Bombay, 8, 421-461.
77. PARKER, L.A. & KEMP, S.W. (2001). Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV). NeuroReport, 12, 749-751.
78. PARKER, L.A., KWIATKOWSKA, M., BURTON, P. & MECHOULAM, R. (2004). Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl.), 171, 156-161.
79. PARKER, L.A., MECHOULAM, R. & SCHLIEVERT, C. (2002). Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. NeuroReport, 13, 567-570.
80. PARKER, L.A., MECHOULAM, R., SCHLIEVERT, C., ABBOTT, L., FUDGE, M.L. & BURTON, P. (2003). Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl.), 166, 156-162.
81. PAROLARO, D., MASSI, P., RUBINO, T. & MONTI, E. (2002). Endocannabinoids in the immune system and cancer. Prostaglandins Leukot. Essent. Fatty Acids, 66, 319-332.
82. PARTOSOEDARSO, E., DINH, N.T. & HORNBY, P.J. (2003a). Endocannabinoids can alter gastric volume via CB1 receptors in rats. Neurogastroenterol Motil., 15, 215.
83. PARTOSOEDARSO, E.R., ABRAHAMS, T.P., SCULLION, R.T., MOERSCHBAECHER, J.M. & HORNBY, P.J. (2003b). Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J. Physiol., 550, 149-158.
84. PERTWEE, R.G. (2001). Cannabinoids and the gastrointestinal tract. Gut, 48, 859-867.
85. PERTWEE, R.G., FERNANDO, S.R., NASH, J.E. & COUTTS, A.A. (1996). Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br. J. Pharmacol., 118, 2199-2205.
86. PINTO, L., CAPASSO, R., DI CARLO, G. & IZZO, A.A. (2002a). Endocannabinoids and the gut. Prostaglandins Leukot. Essent. Fatty Acids, 66, 333-341.
87. PINTO, L., IZZO, A.A., CASCIO, M.G., BISOGNO, T., HOSPODAR-SCOTT, K., BROWN, D.R., MASCOLO, N., DI MARZO, V. & CAPASSO, F. (2002b). Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology, 123, 227-234.
88. PORTER, A.C., SAUER, J.M., KNIERMAN, M.D., BECKER, G.W., BERNA, M.J., BAO, J., NOMIKOS, G.G., CARTER, P., BYMASTER, F.P., LEESE, A.B. & FELDER, C.C. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 301, 1020-1024.
89. RICE, A.S., FARQUHAR-SMITH, W.P. & NAGY, I. (2002). Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot. Essent. Fatty Acids, 66, 243-256.
90. ROBERTS, J.C., DAVIS, J.B. & BENHAM, C.D. (2004). [3H]Resiniferatoxin autoradiography in the CNS of wild-type and DIARRHOEA null mice defines DIARRHOEA (VR-1) protein distribution. Brain Res., 995, 176-183.
91. ROFFMAN, R.A. (1982). Marijuana as Medicine. Seattle: Madrona Publishers.
92. SCHAFFER, J.E. & LODISH, H.F. (1994). Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell, 79, 427-436.
93. SCHMID, P.C., SCHWINDENHAMMER, D., KREBSBACH, R.J. & SCHMID, H.H. (1998). Alternative pathways of anandamide biosynthesis in rat testes. Chem. Phys. Lipids, 92, 27-35.
94. SHOOK, J.E. & BURKS, T.F. (1989). Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J. Pharmacol. Exp. Ther., 249, 444-449.
95. SIMONEAUII, HAMZA, M.S., MATA, H.P., SIEGEL, E.M., VANDERAH, T.W., PORRECA, F., MAKRIYANNIS, A & MALAN Jr, T.P. (2001). The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology, 94, 882-887.
96. STELLA, N. & PIOMELLI, D. (2001). Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol., 425, 189-196.
97. STORR, M., SIBAEV, A., MARSICANO, G., LUTZ, B., SCHUSDZIARRA, V., TIMMERMANS, J.P. & ALLESCHER, H.D. (2004). Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am. J. Physiol. Gastrointest Liver Physiol., 286, G110-G117.
98. SUGIURA, T., KOBAYASHI, Y., OKA, S. & WAKU, K. (2002). Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot. Essent. Fatty Acids, 66, 173-192.
99. SUGIURA, T., KONDO, S., KISHIMOTO, S., MIYASHITA, T., NAKANE, S., KODAKA, T., SUHARA, Y., TAKAYAMA, H. & WAKU, K. (2000). Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem., 275, 605-612.
100. TRAMER, M.R., CARROLL, D., CAMPBELL, F.A., REYNOLDS, D.J., MOORE, R.A. & MCQUAY, H.J. (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ, 323, 16-21.
101. TRAVAGLI, R.A., GILLIS, R.A., ROSSITER, C.D. & VICINI, S. (1991). Glutamate and GABA-mediated synaptic currents in neurons of the rat dorsal motor nucleus of the vagus. Am. J. Physiol., 260, G531-G536.
102. TSOU, K., NOGUERON, M.I., MUTHIAN, S., SANUDO-PENA, M.C., HILLARD, C.J., DEUTSCH, D.G. & WALKER, J.M. (1998). Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci. Lett., 254, 137-140.
103. TYLER, K., HILLARD, C.J. & GREENWOOD-VAN MEERVELD, B. (2000). Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur. J. Pharmacol., 409, 207-211.
104. VAN SICKLE, M.D., OLAND, L.D., HO, W., HILLARD, C.J., MACKIE, K., DAVISON, J.S. & SHARKEY, K.A. (2001). Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology, 121, 767-774.
105. VAN SICKLE, M.D., OLAND, L.D., MACKIE, K., DAVISON, J.S. & SHARKEY, K.A. (2003). Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am. J. Physiol. Gastrointest. Liver Physiol., 285, G566-G576.
106. ZHANG, Q., LEHMANN, A., RIGDA, R., DENT, J. & HOLLOWAY, R.H. (2002). Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut, 50, 19-24.